Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.

abstract：:There is growing evidence that combinations of antiangiogenic proteins with other antineoplastic treatments such as chemo- or radiotherapy and suicide genes-mediated tumor cytotoxicity lead to synergistic effects. In the present work, we tested the activity of two non-replicative herpes simplex virus (HSV)-1-based vec...

journal_title：Cancer gene therapy

authors： Berto E,Bozac A,Volpi I,Lanzoni I,Vasquez F,Melara N,Manservigi R,Marconi P

更新日期：2007-09-01 00:00:00

abstract：:Mammary carcinomas that develop in C3 (1)/SV40 T- antigen (TAg) transgenic mice have lost the p53-mediated induction of p21, leading to increased cellular proliferation and significant elevations of cyclins and Cdks. To test whether p21 could serve as a target for anticancer therapy for this mammary cancer model, a re...

journal_title：Cancer gene therapy

authors： Shibata MA,Yoshidome K,Shibata E,Jorcyk CL,Green JE

更新日期：2001-01-01 00:00:00

abstract：:Replication-competent adenoviruses (Ads) were used for oncolytic virotherapy soon after they were discovered. Recently mutated and genetically engineered Ads have been shown to selectively lyse tumor cells. We have split the human Ad type 5 genome into two defective viruses that complement each other only in certain t...

journal_title：Cancer gene therapy

authors： Alemany R,Lai S,Lou YC,Jan HY,Fang X,Zhang WW

更新日期：1999-01-01 00:00:00

abstract：:We demonstrated that enhanced expression of the costimulatory molecules CD80, CD54 and CD48 (designated rF-TRICOM) on target cells, as delivered via a recombinant fowlpox vector, results in an increased state of stimulation of CD8+ T cells, and consequent increased lysis of target cells. CTL studies in conjunction wit...

journal_title：Cancer gene therapy

authors： Slavin-Chiorini DC,Catalfamo M,Kudo-Saito C,Hodge JW,Schlom J,Sabzevari H

更新日期：2004-10-01 00:00:00

abstract：:Targeting tumor vasculature represents an interesting approach for the treatment of solid tumors. The alpha v beta 3 integrins have been found to be specifically associated with angiogenesis in tumors. By using bacteriophage display technology, Ruoslahti et al found that a group of peptides containing the RGD (Arg-Gly...

journal_title：Cancer gene therapy

authors： Li J,Ji J,Holmes LM,Burgin KE,Barton LB,Yu X,Wagner TE,Wei Y

更新日期：2004-05-01 00:00:00

abstract：:NPS-2143 is a calcium-sensing receptor (CaSR) antagonist that has been demonstrated to possess anticancer activity. To date, the effects of NPS-2143 on gastric cancer (GC) cell growth, motility, and apoptosis have not been investigated. In the present study, we firstly investigated the expression of CaSR in GC tissues...

journal_title：Cancer gene therapy

authors： Zhang ZL,Li ZR,Li JS,Wang SR

更新日期：2020-08-01 00:00:00

abstract：:The herpes simplex virus thymidine kinase (HSV-TK) gene is being developed in the treatment of many different types of tumors. The HSV-TK gene sensitizes tumor cells to the antiviral drug ganciclovir (GCV) and mediates the bystander effect in which unmodified tumor cells are killed as well. Although this approach has ...

journal_title：Cancer gene therapy

authors： Whartenby KA,Darnowski JW,Freeman SM,Yurasha K,Calabresi P

更新日期：1999-09-01 00:00:00

abstract：:Gene therapy for prostate cancer may be realized through transduction of whole genes, such as PSA or PSMA, into immunotherapeutic dendritic cells (DCs). An oncoretroviral vector encoding human PSMA and a bicistronic oncoretroviral vector encoding human PSA and cell surface CD25 cDNAs were constructed. Remarkably, tran...

journal_title：Cancer gene therapy

authors： Medin JA,Liang SB,Hou JW,Kelley LS,Peace DJ,Fowler DH

更新日期：2005-06-01 00:00:00

abstract：:A novel gene, HA117, was discovered in our previous work. Using the pSOS-HUS vector method which we designed at previous study, we screened for small interfering RNAs (siRNAs) that targeted HA117. The pSOS-HUS siRNA screening results were verified and a delivery system was developed that contained a recombinant adenov...

journal_title：Cancer gene therapy

authors： Zheng GH,Luo Q,Jin XQ,Guo YX,Xu YH

更新日期：2011-09-01 00:00:00

abstract：:Due to the lack of early diagnostic and effective treatment modalities, hepatocellular carcinoma (HCC) is still the most lethal cancer with a high mortality on a global scale. Recent studies have highlighted the key roles of microRNAs (miRs) in HCC development. In the study, we attempted to investigate the potential r...

journal_title：Cancer gene therapy

authors： Si T,Ning X,Zhao H,Zhang M,Huang P,Hu Z,Yang L,Lin L

更新日期：2020-11-30 00:00:00

abstract：:Screening and identifying molecules target to checkpoint pathways has fostered the development of checkpoint-based anticancer strategies. Among these targets, inhibition of chk2 may induce cell death for tumors whose growth depends on enhanced chk2 activity. However, improvement of the potency and specificity of such ...

journal_title：Cancer gene therapy

authors： Chen G,Zhou J,Gao Q,Huang X,Li K,Zhuang L,Huang M,Xu G,Wang S,Lu Y,Ma D

更新日期：2006-10-01 00:00:00

abstract：:Oncolytic herpes simplex virus (oHSV)-1-based vectors selectively replicate in tumor cells causing direct killing, that is, oncolysis, while sparing normal cells. The oHSVs are promising anticancer agents, but their efficacy, when used as single agents, leaves room for improvement. We hypothesized that combining the d...

journal_title：Cancer gene therapy

authors： Passer BJ,Cheema T,Wu S,Wu CL,Rabkin SD,Martuza RL

更新日期：2013-01-01 00:00:00

abstract：:We report that radiation enhances the antitumor efficacy of the oncolytic adenovirus vector VRX-007 in Syrian hamster tumors. We used tumor-specific irradiation of subcutaneous tumors and compared treatment options of radiation alone or combined with VRX-007 and cyclophosphamide (CP). Radiation therapy further augment...

journal_title：Cancer gene therapy

authors： Young BA,Spencer JF,Ying B,Toth K,Wold WS

更新日期：2013-09-01 00:00:00

abstract：:We have examined the effect of adenoviruses expressing soluble transforming growth factor receptorII-Fc (sTGFβRIIFc) in a 4T1 mouse mammary tumor bone metastasis model using syngeneic BALB/c mice. Infection of 4T1 cells with a non-replicating adenovirus, Ad(E1-).sTβRFc, or with two oncolytic adenoviruses, Ad.sTβRFc an...

journal_title：Cancer gene therapy

authors： Zhang Z,Hu Z,Gupta J,Krimmel JD,Gerseny HM,Berg AF,Robbins JS,Du H,Prabhakar B,Seth P

更新日期：2012-09-01 00:00:00

abstract：:The prognosis of glioblastoma remains poor despite intensive research efforts. Glioblastoma stem cells (GSCs) contribute to tumorigenesis, invasive capacity, and therapy resistance. Leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5), a stem cell marker, is involved in the maintenance of GSCs, although ...

journal_title：Cancer gene therapy

authors： Tanigawa S,Fujita M,Moyama C,Ando S,Ii H,Kojima Y,Fujishita T,Aoki M,Takeuchi H,Yamanaka T,Takahashi Y,Hashimoto N,Nakata S

更新日期：2021-01-07 00:00:00

abstract：:Most advanced solid tumors metastasize to different organs. However, no gene therapy effective for multiple tumors has yet been developed. Since a unique characteristic of bone marrow-derived mesenchymal stem cells (MSCs) is that they migrate to tumor tissues, we wanted to determine whether MSCs could serve as a vehic...

journal_title：Cancer gene therapy

authors： Kanehira M,Xin H,Hoshino K,Maemondo M,Mizuguchi H,Hayakawa T,Matsumoto K,Nakamura T,Nukiwa T,Saijo Y

更新日期：2007-11-01 00:00:00

abstract：:Mesenchymal stem cells (MSCs) have affinity to tumor sites where they home, affecting their biology and growth. Previously, we have isolated mesenchymal cells from the decidua of the human placenta named as decidua-derived MSCs (DMSCs). The aims of the present study were to investigate the migration capacity of DMSCs ...

journal_title：Cancer gene therapy

authors： Vegh I,Grau M,Gracia M,Grande J,de la Torre P,Flores AI

更新日期：2013-01-01 00:00:00

abstract：:The DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT) is epigenetically silenced in some tumors by MGMT gene promoter methylation. MGMT-hypermethylated solid tumors have enhanced susceptibility to the cytotoxic effects of alkylating chemotherapy such as temozolomide, compared with non-methylated tumors. ...

journal_title：Cancer gene therapy

authors： Ambady P,Wu YJ,Walker JM,Kersch C,Pagel MA,Woltjer RL,Fu R,Muldoon LL,Neuwelt EA

更新日期：2017-08-01 00:00:00

abstract：:Engineered retroviruses are widely used vectors for cancer gene therapy approaches. However, the ability to target cells of therapeutic interest while controlling the expression of the transferred genes would improve both the efficiency and the safety of viral vectors. In this study, we investigated the ability of a r...

journal_title：Cancer gene therapy

authors： Nguyen TH,Loux N,Dagher I,Vons C,Carey K,Briand P,Hadchouel M,Franco D,Jouanneau J,Schwall R,Weber A

更新日期：2003-11-01 00:00:00

abstract：:Ad-PPE-Fas-c is an adenovector that expresses Fas-c under the control of the modified pre-proendothelin-1 (PPE-1) promoter. Fas-c is a chimeric death receptor containing the extracellular portion of tumour necrosis factor 1 receptor (TNFR1) and the transmembrane and intracellular portion of Fas. We recently demonstrat...

journal_title：Cancer gene therapy

authors： Peled M,Shaish A,Greenberger S,Katav A,Hodish I,Ben-Shushan D,Barshack I,Mendel I,Frishman L,Tal R,Bangio L,Breitbart E,Harats D

更新日期：2008-08-01 00:00:00

abstract：:Although early stage cholangiocarcinoma (CC) can be cured by surgical extirpation, the options for treatment of advanced stage CC are very few and suboptimal. Oncolytic virotherapy using replication-competent vaccinia virus (VACV) is a promising new strategy to treat human cancers. The ability of oncolytic VACV GLV-1h...

journal_title：Cancer gene therapy

authors： Pugalenthi A,Mojica K,Ady JW,Johnsen C,Love D,Chen NG,Aguilar RJ,Szalay AA,Fong Y

更新日期：2015-12-01 00:00:00

abstract：:RNA interference is an endogenous gene-silencing mechanism that involves double-stranded RNA-mediated sequence-specific mRNA degradation. The discovery of this pathway together with the elucidation of the structure and function of short interfering RNAs--the effector molecules of RNA interference--has had an enormous ...

journal_title：Cancer gene therapy

authors： Karagiannis TC,El-Osta A

更新日期：2005-10-01 00:00:00

abstract：:Apatinib, a selective vascular endothelial growth factor receptor 2-tyrosine kinase inhibitor, has demonstrated activity against a wide range of solid tumors, including advanced hepatocellular carcinoma (HCC). Preclinical and preliminary clinical results have confirmed the synergistic antitumor effects of apatinib in ...

journal_title：Cancer gene therapy

authors： Yang Y,Wang C,Sun H,Jiang Z,Zhang Y,Pan Z

更新日期：2020-06-12 00:00:00

abstract：:Earlier, we reported an association of A-kinase anchor protein 4 (AKAP4) expression in cervical cancer patient specimens, indicating its implications as an immunotherapeutic target. In this study, we investigated the possible role of AKAP4 in cervical carcinogenesis. AKAP4 messenger RNA and protein expression was asse...

journal_title：Cancer gene therapy

authors： Saini S,Agarwal S,Sinha A,Verma A,Parashar D,Gupta N,Ansari AS,Lohiya NK,Jagadish N,Suri A

更新日期：2013-07-01 00:00:00

abstract：:Malignant tumors express tumor-related antigens, but effective antitumor immunity does not occur in the primary host. One hypothesis is that there is insufficient stimulation of T-cell responses due to ineffective antigen presentation. An approach to overcome these deficiencies is to modify tumor cells to express majo...

journal_title：Cancer gene therapy

authors： Hock RA,Reynolds BD,Tucker-McClung CL,Heuer JG

更新日期：1996-09-01 00:00:00

abstract：:Poor tumor targeting of oncolytic adenoviruses (OAdv) after systemic administration is considered a major limitation for virotherapy of disseminated cancers. The benefit of using mesenchymal stem cells as cell carriers for OAdv tumor targeting is currently evaluated not only in preclinical models but also in clinical ...

journal_title：Cancer gene therapy

authors： Barlabé P,Sostoa J,Fajardo CA,Alemany R,Moreno R

更新日期：2020-05-01 00:00:00

abstract：:Delivery of the full-length tumor antigen might be more successful in immunotherapy than single peptides and has the advantage that patients no longer need to be selected for their HLA type. In this study, we tested the in vitro induction of CAMEL/NY-ESO-ORF2-specific T cells by dendritic cells infected with an adenov...

journal_title：Cancer gene therapy

authors： Slager EH,van der Minne CE,Goudsmit J,van Oers JM,Kostense S,Havenga MJ,Osanto S,Griffioen M

更新日期：2004-03-01 00:00:00

abstract：:Arming oncolytic adenoviral vectors with anticancer transgenes that can be expressed in a tumor-selective manner may enable the engineering of vectors with increased potency, while retaining their safety profile. Armed oncolytic adenoviral vectors were constructed in which transgene expression has been linked via modi...

journal_title：Cancer gene therapy

authors： Robinson M,Ge Y,Ko D,Yendluri S,Laflamme G,Hawkins L,Jooss K

更新日期：2008-01-01 00:00:00

abstract：:CD4+CD25+regulatory T cells (T(reg)) impair anti-tumor and anti-viral immunity. As there are higher T(reg) levels in cancer patients compared with healthy individuals, there is considerable interest in eliminating them or altering their function as part of cancer or viral immunotherapy strategies. The scurfin transcri...

journal_title：Cancer gene therapy

authors： Morse MA,Hobeika A,Serra D,Aird K,McKinney M,Aldrich A,Clay T,Mourich D,Lyerly HK,Iversen PL,Devi GR

更新日期：2012-01-01 00:00:00

abstract：:Hepatocellular carcinoma (HCC) recurrence is one of the leading causes of death after orthotopic liver transplantation (OLT). The sixth complement component (C6) is a late-acting complement protein that participates in the assembly of the membrane attack complex, which has an indispensable role in innate and acquired ...

journal_title：Cancer gene therapy

authors： Wang Z,Liao J,Wu S,Li C,Fan J,Peng Z

更新日期：2016-06-01 00:00:00